These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31679559)

  • 1. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.
    do Nascimento CC; Aguiar O; Viana GM; D Almeida V
    Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological damage in Sertoli, myoid and interstitial cells in a mouse model of mucopolysaccharidosis type I (MPS I).
    do Nascimento CC; Aguiar O; Viana GM; D'Almeida V
    Mol Biol Rep; 2021 Jan; 48(1):363-370. PubMed ID: 33319323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).
    do Nascimento CC; Junior OA; D'Almeida V
    J Mol Histol; 2020 Apr; 51(2):137-145. PubMed ID: 32162173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).
    Barbosa Mendes A; do Nascimento CC; D'Almeida V
    PLoS One; 2019; 14(12):e0220429. PubMed ID: 31834922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
    Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
    Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomechanical and histological characterization of MPS I mice femurs.
    Ferreira NY; do Nascimento CC; Pereira VG; de Oliveira F; Medalha CC; da Silva VC; D'Almeida V
    Acta Histochem; 2021 Feb; 123(2):151678. PubMed ID: 33434858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of male reproductive parameters in a murine model of mucopolysaccharidosis type I (MPS I).
    do Nascimento CC; Junior OA; D'Almeida V
    Int J Clin Exp Pathol; 2014; 7(6):3488-97. PubMed ID: 25031781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
    Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
    Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
    Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
    Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
    Clarke LA; Russell CS; Pownall S; Warrington CL; Borowski A; Dimmick JE; Toone J; Jirik FR
    Hum Mol Genet; 1997 Apr; 6(4):503-11. PubMed ID: 9097952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
    Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
    Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.
    Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T
    Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of joint disease in mucopolysaccharidosis type I mice.
    de Oliveira PG; Baldo G; Mayer FQ; Martinelli B; Meurer L; Giugliani R; Matte U; Xavier RM
    Int J Exp Pathol; 2013 Oct; 94(5):305-11. PubMed ID: 23786352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I.
    Wolf DA; Lenander AW; Nan Z; Braunlin EA; Podetz-Pedersen KM; Whitley CB; Gupta P; Low WC; McIvor RS
    Bone Marrow Transplant; 2012 Sep; 47(9):1235-40. PubMed ID: 22179554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased performance in IDUA knockout mouse mimic limitations of joint function and locomotion in patients with Hurler syndrome.
    Kim C; Kwak MJ; Cho SY; Ko AR; Rheey J; Kwon JY; Chung Y; Jin DK
    Orphanet J Rare Dis; 2015 Sep; 10():121. PubMed ID: 26407983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Molecular Characterization of Patients with Mucopolysaccharidosis Type I in an Algerian Series.
    Tebani A; Zanoutene-Cheriet L; Adjtoutah Z; Abily-Donval L; Brasse-Lagnel C; Laquerrière A; Marret S; Chalabi Benabdellah A; Bekri S
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
    Ou L; Przybilla MJ; Koniar B; Whitley CB
    Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.